Table of Contents
Advances in Vascular Medicine
Volume 2014 (2014), Article ID 689815, 11 pages
http://dx.doi.org/10.1155/2014/689815
Review Article

Diverse Functions of Secretory Phospholipases A2

1Department of Internal Medicine, Division of Endocrinology and Cardiovascular Research Center, University of Kentucky, 900 S. Limestone, 567 Wethington Building, Lexington, KY 40536-0200, USA
2Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, KY 40536-0200, USA

Received 7 May 2014; Accepted 21 June 2014; Published 15 July 2014

Academic Editor: David Tanne

Copyright © 2014 Preetha Shridas and Nancy R. Webb. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Murakami, Y. Taketomi, H. Sato, and K. Yamamoto, “Secreted phospholipase A2 revisited,” Journal of Biochemistry, vol. 150, no. 3, pp. 233–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. C. M. Mounier, F. Ghomashchi, M. R. Lindsay et al., “Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A2 occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A2-α,” Journal of Biological Chemistry, vol. 279, no. 24, pp. 25024–25038, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Murakami and I. Kudo, “Diversity and regulatory functions of mammalian secretory phospholipase A2s,” Advances in Immunology, vol. 77, pp. 163–194, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Kudo and M. Murakami, “Phospholipase A2 enzymes,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 3–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto, “Recent progress in phospholipase A2 research: from cells to animals to humans,” Progress in Lipid Research, vol. 50, no. 2, pp. 152–192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Valentines, F. Ghomashchi, M. H. Gelb, M. Lazdunski, and G. Lambeau, “Novel human secreted phospholipase A2 with homology to the group III bee venom enzyme,” Journal of Biological Chemistry, vol. 275, no. 11, pp. 7492–7496, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Rouault, J. G. Bollinger, M. Lazdunski, M. H. Gelb, and G. Lambeau, “Novel mammalian group XII secreted phospholipase A2 lacking enzymatic activity,” Biochemistry, vol. 42, no. 39, pp. 11494–11503, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto, “Recent progress in phospholipase A2 research: from cells to animals to humans,” Progress in Lipid Research, vol. 50, no. 2, pp. 152–192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Murakami, Y. Taketomi, C. Girard, K. Yamamoto, and G. Lambeau, “Emerging roles of secreted phospholipase A2 enzymes: lessons from transgenic and knockout mice,” Biochimie, vol. 92, no. 6, pp. 561–582, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. B. B. Boyanovsky and N. R. Webb, “Biology of secretory phospholipase A2,” Cardiovascular Drugs and Therapy, vol. 23, no. 1, pp. 61–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Lambeau and M. H. Gelb, “Biochemistry and physiology of mammalian secreted phospholipases A 2,” Annual Review of Biochemistry, vol. 77, pp. 495–520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Matsuoka, M. Hirata, H. Tanaka et al., “Prostaglandin D2 as a mediator of allergic asthma,” Science, vol. 287, no. 5460, pp. 2013–2017, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Terawaki, T. Yokomizo, T. Nagase et al., “Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses,” Journal of Immunology, vol. 175, no. 7, pp. 4217–4225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Tager, S. K. Bromley, B. D. Medoff et al., “Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment,” Nature Immunology, vol. 4, no. 10, pp. 982–990, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Jaffar, M. E. Ferrini, M. C. Buford, G. A. FitzGerald, and K. Roberts, “Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma,” Journal of Immunology, vol. 179, no. 9, pp. 6193–6203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Kunikata, H. Yamane, E. Segi et al., “Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3,” Nature Immunology, vol. 6, no. 5, pp. 524–531, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. C. G. Irvin, Y. Tu, J. R. Sheller, and C. D. Funk, “5-lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 272, no. 6, pp. L1053–L1058, 1997. View at Google Scholar · View at Scopus
  18. B. D. Levy, G. T. De Sanctis, P. R. Devchand et al., “Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4,” Nature Medicine, vol. 8, no. 9, pp. 1018–1023, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Haworth, M. Cernadas, R. Yang, C. N. Serhan, and B. D. Levy, “Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammation,” Nature Immunology, vol. 9, no. 8, pp. 873–879, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Offer, S. Yedgar, O. Schwob et al., “Negative feedback between secretory and cytosolic phospholipase A2 and their opposing roles in ovalbumin-induced bronchoconstriction in rats,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 288, no. 3, pp. L523–L529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. T. S. Hallstrand and W. R. Henderson Jr., “Role of leukotrienes in exercise-induced bronchoconstriction,” Current Allergy and Asthma Reports, vol. 9, no. 1, pp. 18–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. E. A. Capper and L. A. Marshall, “Mammalian phospholipases A2: mediators of inflammation, proliferation and apoptosis,” Progress in Lipid Research, vol. 40, no. 3, pp. 167–197, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. N. M. Muñoz, Y. J. Kim, A. Y. Meliton et al., “Human group V phospholipase A2 induces group IVA phospholipase A2-independent cysteinyl leukotriene synthesis in human eosinophils,” The Journal of Biological Chemistry, vol. 278, no. 40, pp. 38813–38820, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. N. J. Pyne, D. Tolan, and S. Pyne, “Bradykinin stimulates cAMP synthesis via mitogen-activated protein kinase-dependent regulation of cytosolic phospholipase A2 and prostaglandin E2 release in airway smooth muscle,” Biochemical Journal, vol. 328, part 2, pp. 689–694, 1997. View at Google Scholar · View at Scopus
  25. A. C. Sane, T. Mendenhall, and D. A. Bass, “Secretory phospholipase A2 activity is elevated in bronchoalveolar lavage fluid after ovalbumin sensitization of guinea pigs,” Journal of Leukocyte Biology, vol. 60, no. 6, pp. 704–709, 1996. View at Google Scholar · View at Scopus
  26. P. Vadas, “Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid,” Biochimica et Biophysica Acta, vol. 1346, no. 2, pp. 193–197, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Triggiani, F. Granata, A. Petraroli et al., “Inhibition of secretory phospholipase A2-induced cytokine production in human lung macrophages by budesonide,” International Archives of Allergy and Immunology, vol. 150, no. 2, pp. 144–155, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. D. L. Bowton, M. C. Seeds, M. B. Fasano, B. Goldsmith, and D. A. Bass, “Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics,” The American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 2, pp. 421–425, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. F. H. Chilton, F. J. Averill, W. C. Hubbard, A. N. Fonteh, M. Triggiani, and M. C. Liu, “Antigen-induced generation of lyso-phospholipids in human airways,” Journal of Experimental Medicine, vol. 183, no. 5, pp. 2235–2245, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Stadel, K. Hoyle, R. M. Naclerio, A. Roshak, and F. H. Chilton, “Characterization of phospholipase A2 from human nasal lavage.,” American Journal of Respiratory Cell and Molecular Biology, vol. 11, no. 1, pp. 108–113, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. T. S. Hallstrand, Y. Lai, Z. Ni et al., “Relationship between levels of secreted phospholipase A2 groups IIA and X in the airways and asthma severity,” Clinical and Experimental Allergy, vol. 41, no. 6, pp. 801–810, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. G. Singer, F. Ghomashchi, C. Le Calvez et al., “Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2,” Journal of Biological Chemistry, vol. 277, no. 50, pp. 48535–48549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. W. R. Henderson Jr., E. Y. Chi, J. G. Bollinger et al., “Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model,” The Journal of Experimental Medicine, vol. 204, no. 4, pp. 865–877, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. T. S. Hallstrand, E. Y. Chi, A. G. Singer, M. H. Gelb, and W. R. Henderson Jr., “Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness,” The American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 11, pp. 1072–1078, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Lai, R. C. Oslund, J. G. Bollinger et al., “Eosinophil cysteinyl leukotriene synthesis mediated by exogenous secreted phospholipase A2 group X,” Journal of Biological Chemistry, vol. 285, no. 53, pp. 41491–41500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. T. S. Hallstrand, Y. Lai, W. A. Altemeier et al., “Regulation and function of epithelial secreted phospholipase A2 group X in asthma,” The American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 1, pp. 42–50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. W. R. Henderson Jr., R. C. Oslund, J. G. Bollinger et al., “Blockade of human group X secreted phospholipase A 2 (GX-sPLA 2)-induced airway inflammation and hyperresponsiveness in a mouse asthma model by a selective GX-sPLA 2 inhibitor,” Journal of Biological Chemistry, vol. 286, no. 32, pp. 28049–28055, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Degousee, D. J. Kelvin, G. Geisslinger et al., “Group V phospholipase A2 in bone marrow-derived myeloid cells and bronchial epithelial cells promotes bacterial clearance after Escherichia coli pneumonia,” The Journal of Biological Chemistry, vol. 286, no. 41, pp. 35650–35662, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. N. M. Muñoz, A. Y. Meliton, J. P. Arm, J. V. Bonventre, W. Cho, and A. R. Leff, “Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice,” Journal of Immunology, vol. 179, no. 7, pp. 4800–4807, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Giannattasio, D. Fujioka, W. Xing, H. R. Katz, J. A. Boyce, and B. Balestrieri, “Group v secretory phospholipase A2 reveals its role in house dust mite-induced allergic pulmonary inflammation by regulation of dendritic cell function,” Journal of Immunology, vol. 185, no. 7, pp. 4430–4438, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Balestrieri, A. Maekawa, W. Xing, M. H. Gelb, H. R. Katz, and J. P. Arm, “Group V secretory phospholipase A2 modulates phagosome maturation and regulates the innate immune response against Candida albicans,” Journal of Immunology, vol. 182, no. 8, pp. 4891–4898, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Lapointe, A. Brkovic, I. Cloutier, J. Tanguay, J. P. Arm, and M. G. Sirois, “Group V secreted phospholipase A2 contributes to LPS-induced leukocyte recruitment,” Journal of Cellular Physiology, vol. 224, no. 1, pp. 127–134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Ohtsuki, Y. Taketomi, S. Arata et al., “Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction,” Journal of Biological Chemistry, vol. 281, no. 47, pp. 36420–36433, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. A. A. Kelvin, N. Degousee, D. Banner et al., “Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection,” Virology, vol. 454-455, pp. 78–92, 2014. View at Google Scholar
  45. A. Enomoto, M. Murakami, E. Valentin, G. Lambeau, M. H. Gelb, and I. Kudo, “Redundant and segregated functions of granule-associated heparin-binding group II subfamily of secretory phospholipases A2 in the regulation of degranulation and prostaglandin D2 synthesis in mast cells,” The Journal of Immunology, vol. 165, no. 7, pp. 4007–4014, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. M. A. Balboa, J. Balsinde, M. V. Winstead, J. A. Tischfield, and E. A. Dennis, “Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages,” Journal of Biological Chemistry, vol. 271, no. 50, pp. 32381–32384, 1996. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Masuda, M. Murakami, M. Mitsuishi et al., “Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells,” Biochemical Journal, vol. 387, no. 1, pp. 27–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Hamaguchi, H. Kuwata, K. Yoshihara et al., “Induction of distinct sets of secretory phospholipase A2 in rodents during inflammation,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1635, no. 1, pp. 37–47, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Movert, Y. Wu, G. Lambeau, F. Kahn, L. Touqui, and T. Areschoug, “Secreted group iia phospholipase a2 protects humans against the group b streptococcus: experimental and clinical evidence,” The Journal of Infectious Diseases, vol. 208, pp. 2025–2035, 2013. View at Publisher · View at Google Scholar
  50. A. Piris-Gimenez, M. Paya, G. Lambeau et al., “In vivo protective role of human group IIA phospholipase A2 against experimental anthrax,” The Journal of Immunology, vol. 175, no. 10, pp. 6786–6791, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Granata, A. Frattini, S. Loffredo et al., “Signaling events involved in cytokine and chemokine production induced by secretory phospholipase A2 in human lung macrophages,” European Journal of Immunology, vol. 36, no. 7, pp. 1938–1950, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Balestrieri and J. P. Arm, “Group V sPLA2: classical and novel functions,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1761, no. 11, pp. 1280–1288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Mitsuishi, S. Masuda, I. Kudo, and M. Murakami, “Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells,” Biochemical Journal, vol. 393, no. 1, pp. 97–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Kimura-Matsumoto, Y. Ishikawa, K. Komiyama et al., “Expression of secretory phospholipase A2s in human atherosclerosis development,” Atherosclerosis, vol. 196, no. 1, pp. 81–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Hanasaki, K. Yamada, S. Yamamoto et al., “Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation,” Journal of Biological Chemistry, vol. 277, no. 32, pp. 29116–29124, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. S. A. I. Ghesquiere, M. J. J. Gijbels, M. Anthonsen et al., “Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition,” Journal of Lipid Research, vol. 46, no. 2, pp. 201–210, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. S. A. Karabina, I. Brochériou, G. le Naour et al., “Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function.,” The FASEB Journal, vol. 20, no. 14, pp. 2547–2549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Jönsson-Rylander, S. Lundin, B. Rosengren, C. Pettersson, and E. Hurt-Camejo, “Role of secretory phospholipases in atherogenesis,” Current Atherosclerosis Reports, vol. 10, no. 3, pp. 252–259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Boyanovsky, M. Zack, K. Forrest, and N. R. Webb, “The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 532–538, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Sato, R. Kato, Y. Isogai et al., “Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis,” The Journal of Biological Chemistry, vol. 283, no. 48, pp. 33483–33497, 2008. View at Publisher · View at Google Scholar
  61. M. A. Bostrom, B. B. Boyanovsky, C. T. Jordan et al., “Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 3, pp. 600–606, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. F. C. De Beer and N. R. Webb, “Inflammation and atherosclerosis: group iia and group v spla2 are not redundant,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1421–1422, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. B. B. Boyanovsky, D. R. van der Westhuyzen, and N. R. Webb, “Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans,” Journal of Biological Chemistry, vol. 280, no. 38, pp. 32746–32752, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Romano, E. Romano, S. Björkerud, and E. Hurt-Camejo, “Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 4, pp. 519–525, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Sartipy, G. Camejo, L. Svensson, and E. Hurt-Camejo, “Phospholipase A2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans,” The Journal of Biological Chemistry, vol. 274, no. 36, pp. 25913–25920, 1999. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Kugiyama, Y. Ota, K. Takazoe et al., “Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease,” Circulation, vol. 100, no. 12, pp. 1280–1284, 1999. View at Publisher · View at Google Scholar · View at Scopus
  67. B. P. Kennedy, P. Payette, J. Mudgett et al., “A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains,” The Journal of Biological Chemistry, vol. 270, no. 38, pp. 22378–22385, 1995. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Ivandic, L. W. Castellani, X. Wang et al., “Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 5, pp. 1284–1290, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. U. J. F. Tietge, C. Maugeais, W. Cain et al., “Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I,” Journal of Biological Chemistry, vol. 275, no. 14, pp. 10077–10084, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. F. C. de Beer, P. M. Connell, J. Yu, M. C. de Beer, N. R. Webb, and D. R. van der Westhuyzen, “HDL modification by secretory phospholipase A2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism,” Journal of Lipid Research, vol. 41, no. 11, pp. 1849–1857, 2000. View at Google Scholar · View at Scopus
  71. N. R. Webb, M. A. Bostrom, S. J. Szilvassy, D. R. van der Westhuyzen, A. Daugherty, and F. C. de Beer, “Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 263–268, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. B. Rosengren, H. Peilot, M. Umaerus et al., “Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a western diet,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1579–1585, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Gesquiere, W. Cho, and P. V. Subbaiah, “Role of group IIa and group V secretory phospholipases A2 in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin,” Biochemistry, vol. 41, no. 15, pp. 4911–4920, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. C. R. Wooton-Kee, B. B. Boyanovsky, M. S. Nasser, W. J. S. de Villiers, and N. R. Webb, “Group V spla2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 4, pp. 762–767, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. B. B. Boyanovsky and N. R. Webb, “Biology of secretory phospholipase A2,” Cardiovascular Drugs and Therapy, vol. 23, no. 1, pp. 61–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Boyanovsky, M. Zack, K. Forrest, and N. R. Webb, “The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 532–538, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Zack, B. B. Boyanovsky, P. Shridas et al., “Group X secretory phospholipase A2 augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice,” Atherosclerosis, vol. 214, no. 1, pp. 58–64, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Ait-Oufella, O. Herbin, C. Lahoute et al., “Group X secreted phospholipase a2 limits the development of atherosclerosis in LDL receptor-null mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 3, pp. 466–473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. S. J. Nicholls, J. J. Kastelein, G. G. Schwartz et al., “Varespladib and cardiovascular events in patients with an acute coronary syndrome: the vista-16 randomized clinical trial,” The Journal of the American Medical Association, vol. 311, pp. 252–262, 2014. View at Google Scholar
  80. T. G. Cooper, “Role of the epididymis in mediating changes in the male gamete during maturation,” Advances in Experimental Medicine and Biology, vol. 377, pp. 87–101, 1995. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Escoffier, I. Jemel, A. Tanemoto et al., “Group X phospholipase A2 is released during sperm acrosome reaction and controls fertility outcome in mice,” The Journal of Clinical Investigation, vol. 120, no. 5, pp. 1415–1428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Escoffier, V. J. Pierre, I. Jemel et al., “Group X secreted phospholipase A2 specifically decreases sperm motility in mice,” Journal of Cellular Physiology, vol. 226, no. 10, pp. 2601–2609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Abi Nahed, J. Escoffier, C. Revel et al., “The effect of group X secreted phospholipase A2 on fertilization outcome is specific and not mimicked by other secreted phospholipases A2 or progesterone,” Biochimie, vol. 99, pp. 88–95, 2014. View at Publisher · View at Google Scholar
  84. H. Sato, Y. Taketomi, Y. Isogai et al., “Group III secreted phospholipase A2 regulates epididymal sperm maturation and fertility in mice,” Journal of Clinical Investigation, vol. 120, no. 5, pp. 1400–1414, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. G. Cavigiolio and S. Jayaraman, “Proteolysis of apolipoprotein a-i by secretory phospholipase a2: a new link between inflammation and atherosclerosis,” The Journal of Biological Chemistry, vol. 289, pp. 10011–10023, 2014. View at Google Scholar
  86. P. Shridas, W. M. Bailey, F. Gizard et al., “Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 10, pp. 2014–2021, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. A. D. Attie, J. P. Kastelein, and M. R. Hayden, “Pivotal role of ABCA1 in reverse cholesterol transport influencing HLD levels and susceptibility to atherosclerosis,” Journal of Lipid Research, vol. 42, no. 11, pp. 1717–1726, 2001. View at Google Scholar · View at Scopus
  88. N. Wang, D. Lan, W. Chen, F. Matsuura, and A. R. Tall, “ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9774–9779, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. P. Costet, Y. Luo, N. Wang, and A. R. Tall, “Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor,” Journal of Biological Chemistry, vol. 275, no. 36, pp. 28240–28245, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Venkateswaran, B. A. Laffitte, S. B. Joseph et al., “Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR α,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12097–12102, 2000. View at Publisher · View at Google Scholar · View at Scopus
  91. T. Yoshikawa, H. Shimano, N. Yahagi et al., “Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements,” Journal of Biological Chemistry, vol. 277, no. 3, pp. 1705–1711, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Ou, H. Tu, B. Shan et al., “Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 11, pp. 6027–6032, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. P. Shridas, W. M. Bailey, F. Gizard et al., “Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 10, pp. 2014–2021, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. X. Zhu, J. Lee, J. M. Timmins et al., “Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages,” Journal of Biological Chemistry, vol. 283, no. 34, pp. 22930–22941, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Li, R. F. Schwabe, T. DeVries-Seimon et al., “Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-α and interleukin-6: model of NF-κB- and map kinase-dependent inflammation in advanced atherosclerosis,” Journal of Biological Chemistry, vol. 280, no. 23, pp. 21763–21772, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Koseki, K. Hirano, D. Masuda et al., “Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-α secretion in Abca1-deficient macrophages,” Journal of Lipid Research, vol. 48, no. 2, pp. 299–306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Yvan-Charvet, C. Welch, T. A. Pagler et al., “Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions,” Circulation, vol. 118, no. 18, pp. 1837–1847, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. P. Shridas, W. M. Bailey, K. R. Talbott, R. C. Oslund, M. H. Gelb, and N. R. Webb, “Group X secretory phospholipase A2 enhances TLR4 signaling in macrophages,” Journal of Immunology, vol. 187, no. 1, pp. 482–489, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. R. Sato, S. Yamaga, K. Watanabe et al., “Inhibition of secretory phospholipase A2 activity attenuates lipopolysaccharide-induced acute lung injury in a mouse model,” Experimental Lung Research, vol. 36, no. 4, pp. 191–200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. P. Shridas, W. M. Bailey, B. B. Boyanovsky, R. C. Oslund, M. H. Gelb, and N. R. Webb, “Group X secretory phospholipase A2 regulates the expression of steroidogenic acute regulatory protein (StAR) in mouse adrenal glands,” Journal of Biological Chemistry, vol. 285, no. 26, pp. 20031–20039, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. D. M. Stocco, “StAR protein and the regulation of steroid hormone biosynthesis,” Annual Review of Physiology, vol. 63, pp. 193–213, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Rigotti, E. R. Edelman, P. Seifert et al., “Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland,” Journal of Biological Chemistry, vol. 271, no. 52, pp. 33545–33549, 1996. View at Publisher · View at Google Scholar · View at Scopus
  103. C. L. Cummins, D. H. Volle, Y. Zhang et al., “Liver X receptors regulate adrenal cholesterol balance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1902–1912, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. K. R. Steffensen, S. Y. Neo, T. M. Stulnig et al., “Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals,” Journal of Molecular Endocrinology, vol. 33, no. 3, pp. 609–622, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. L. K. Juvet, S. M. Andresen, G. U. Schuster et al., “On the role of liver X receptors in lipid accumulation in adipocytes,” Molecular Endocrinology, vol. 17, no. 2, pp. 172–182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. J. B. Seo, H. M. Moon, W. S. Kim et al., “Activated liver x receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor γexpression,” Molecular and Cellular Biology, vol. 24, no. 8, pp. 3430–3444, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. X. Li, P. Shridas, K. Forrest, W. Bailey, and N. R. Webb, “Group X secretory phospholipase a2 negatively regulates adipogenesis in murine models,” FASEB Journal, vol. 24, no. 11, pp. 4313–4324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Fujioka, Y. Saito, T. Kobayashi et al., “Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice,” Circulation, vol. 117, no. 23, pp. 2977–2985, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Guan, L. Qu, W. Tan, L. Chen, and C. Wong, “Hepatocyte nuclear factor-4 alpha regulates liver triglyceride metabolism in part through secreted phospholipase A2 GXIIB,” Hepatology, vol. 53, no. 2, pp. 458–466, 2011. View at Publisher · View at Google Scholar · View at Scopus